[CAS NO. ] KKI-5 TFA

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS

Catalog

HY-P0237A

Brand

MCE

CAS

-

DESCRIPTION

Overview

MDL	-
Molecular Weight	887.90
Molecular Formula	C37H56F3N11O11
SMILES	-

For research use only. We do not sell to patients.

Summary

KKI-5 (TFA) is a specific inhibitor of tissue kallikrein . KKI-5 (TFA) can attenuate breast cancer cell invasion ^[1] .

IC50 & Target

Kallikrein ^[1]

In Vitro

The KKI-5 Peptide corresponds to aa386-391 of bovine kininogen-1 that encompasses the aa388-389 kallikrein proteolytic site. The synthetic KKI-5 can attenuate breast cancer cell invasion, therefore it is investigated for its role in invasion and metastasis of cancer cells ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 9.09 mg/mL ( 10.24 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1263 mL	5.6313 mL	11.2625 mL
5 mM	0.2253 mL	1.1263 mL	2.2525 mL
10 mM	0.1126 mL	0.5631 mL	1.1263 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 12.5 mg/mL (14.08 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

[1] Deshpande MS, et al. Mapping the binding site of tissue kallikrein: preparation and testing of all possible substrate analog inhibitors homologous with the sequence of kininogen between Ser386 and Gln392. J Med Chem. 1992 Aug 21;35(17):3094-102.